A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma.

Trial Profile

A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Nov 2011

At a glance

  • Drugs Gemcitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Pancreatic cancer
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 21 Jul 2009 Actual initiation date (Mar 2003) added as reported by ClinicalTrials.gov.
    • 21 Jul 2009 Actual end date (Jul 2006) added as reported by ClinicalTrials.gov.
    • 06 Jul 2009 Results have been reported in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top